To Study the effects of Unani Formulation Joshanda Aftimoon in patients with Generalized Anxiety Disorder

A study evaluating the therapeutic effects of Joshanda Aftimoon (Decoction of Cuscuta reflexa, Roxb.) in the management of IzterÄ?b-i-NafsÄ?ni Umoomi (Generalized Anxiety Disorder)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/03/050663

Enrollment

Registered

2023-03-14

Start date

Unknown

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F411- Generalized anxiety disorder

Interventions

Intervention1: Joshanda Aftimoon (Decoction of Cuscuta reflexa, Roxb.): It is a classical Unani formulation taken from Unani textbook Bustaan-al-Mufradaat by Hakeem MAH. The Joshanda (Decoction) of Af

Eligibility

Inclusion criteria

Inclusion criteria: Clinically diagnosed patients of Izterab-i-Nafsani Umoomi Patients in age group of 18 to 65 years Irrespective of gender Patients, who are ready to sign the informed consent, follow the protocol and willing to participate in clinical study voluntarily.

Exclusion criteria

Exclusion criteria: Panic disorder, Obsessive Compulsive disorder, Post-traumatic stress disorder,etc. Patients below 18 years and above 65 years. History of substance abuse : Caffeine, Alcohol, Drug intoxication. Patient who fails to follow up. Patient who fails to give written consent. Known cases of Hyperthyroidism, Cardiovascular disease, Renal disease and Liver disease. Pregnant and lactating mother.

Design outcomes

Primary

Measure	Time frame
1.Hamilton Anxiety Rating Scale (HAM-A)24 2.Anxiety State Test (AST)- State-Trait Anxiety Inventory (STAI)23 3.Beck Anxiety Inventory (BAI)32Timepoint: 40 Days	—

Secondary

Measure	Time frame
1.Vegetative manifestations (increased heart rate, diaphoresis, tremor, or dry mouth) 2.Symptoms in the chest or abdomen (respiratory symptoms, feeling of tightness, chest pain, abdominal discomfort) 3.Mental symptoms (dizziness, derealization, fear of losing control, fear of dying) 4.General symptoms (hot or cold flashes, paresthesias) 5.Symptoms of tension (muscle tension, agitation, foreign-body sensation in throat) 6.Other nonspecific symptoms(exaggerated startle response, lack of concentration, irritability, difficulty falling asleep)Timepoint: 40 Days	—

Measure

Time frame

1.Vegetative manifestations (increased heart rate, diaphoresis, tremor, or dry mouth) 2.Symptoms in the chest or abdomen (respiratory symptoms, feeling of tightness, chest pain, abdominal discomfort) 3.Mental symptoms (dizziness, derealization, fear of losing control, fear of dying) 4.General symptoms (hot or cold flashes, paresthesias) 5.Symptoms of tension (muscle tension, agitation, foreign-body sensation in throat) 6.Other nonspecific symptoms(exaggerated startle response, lack of concentration, irritability, difficulty falling asleep)Timepoint: 40 Days

—

Countries

India

Contacts

Public ContactDr Mohammed Sheeraz Mushtaque Ahmed

Regional Research Institute of Unani Medicine (RRIUM) Srinagar

sheeraz.rrium@gmail.com9797750472

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026